Pilot Study on the Efficacy of PegInterferon Alpha-2b-Ribavirin-Boceprevir Triple Therapy in Patients Infected With Genotype 1 HCV With Cirrhosis and Awaiting Liver Transplantation (ANRS HC 29 BOCEPRETRANSPLANT).
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 14 Jan 2015 Planned End Date changed from 1 May 2016 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov